Real world longitudinal study to examine Hizentra 20% subcutaneous therapy (SCIG)-to-intravenous therapy (IVIG) dose ratios in the US after primary immunodeficiency disease (PI) patients are switched from IVIG to 20% SCIG (Hizentra).
Phase of Trial: Phase IV
Latest Information Update: 18 Mar 2018
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- 18 Mar 2018 New trial record